Telomir Pharmaceuticals (TELO) Competitors $1.36 -0.01 (-0.73%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.36 +0.00 (+0.37%) As of 09/12/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TELO vs. ALTS, BTMD, CTOR, SXTC, NVCT, MCRB, LFVN, KYTX, MEIP, and BDTXShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include ALT5 Sigma (ALTS), biote (BTMD), Citius Oncology (CTOR), China SXT Pharmaceuticals (SXTC), Nuvectis Pharma (NVCT), Seres Therapeutics (MCRB), Lifevantage (LFVN), Kyverna Therapeutics (KYTX), MEI Pharma (MEIP), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Its Competitors ALT5 Sigma biote Citius Oncology China SXT Pharmaceuticals Nuvectis Pharma Seres Therapeutics Lifevantage Kyverna Therapeutics MEI Pharma Black Diamond Therapeutics ALT5 Sigma (NASDAQ:ALTS) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership. Which has higher earnings and valuation, ALTS or TELO? ALT5 Sigma has higher revenue and earnings than Telomir Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALT5 Sigma$12.53M7.21-$6.24MN/AN/ATelomir PharmaceuticalsN/AN/A-$16.53M-$0.54-2.52 Which has more volatility and risk, ALTS or TELO? ALT5 Sigma has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of -0.73, indicating that its share price is 173% less volatile than the S&P 500. Do analysts recommend ALTS or TELO? Telomir Pharmaceuticals has a consensus price target of $15.00, indicating a potential upside of 1,002.94%. Given Telomir Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Telomir Pharmaceuticals is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do insiders and institutionals have more ownership in ALTS or TELO? 6.3% of ALT5 Sigma shares are held by institutional investors. 4.9% of ALT5 Sigma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor ALTS or TELO? In the previous week, ALT5 Sigma had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 7 mentions for ALT5 Sigma and 6 mentions for Telomir Pharmaceuticals. ALT5 Sigma's average media sentiment score of 0.44 beat Telomir Pharmaceuticals' score of -0.43 indicating that ALT5 Sigma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Telomir Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Is ALTS or TELO more profitable? Telomir Pharmaceuticals has a net margin of 0.00% compared to ALT5 Sigma's net margin of -74.89%. ALT5 Sigma's return on equity of -179.27% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ALT5 Sigma-74.89% -179.27% -16.28% Telomir Pharmaceuticals N/A -4,595.08%-1,750.91% SummaryALT5 Sigma beats Telomir Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.23M$2.60B$5.85B$10.14BDividend YieldN/A56.52%5.68%4.60%P/E Ratio-2.5223.8575.3425.98Price / SalesN/A529.66514.97181.19Price / CashN/A171.1637.5660.44Price / Book68.005.3712.156.29Net Income-$16.53M$32.95M$3.29B$271.07M7 Day Performance9.68%1.28%0.75%3.87%1 Month Performance-15.00%6.09%4.82%4.88%1 Year Performance-77.59%-2.15%60.59%26.12% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals1.9975 of 5 stars$1.36-0.7%$15.00+1,002.9%-77.1%$44.23MN/A-2.521Short Interest ↑ALTSALT5 Sigma0.2103 of 5 stars$5.58-29.2%N/A+84.1%$170.28M$12.53M0.00170Short Interest ↑High Trading VolumeBTMDbiote3.0345 of 5 stars$3.43-0.3%$6.00+74.9%-41.2%$170.07M$197.19M3.81194Positive NewsCTORCitius Oncology1.8034 of 5 stars$2.01-7.4%$3.00+49.3%+16.5%$170.06MN/A0.00N/ASXTCChina SXT Pharmaceuticals1.3055 of 5 stars$1.42-2.7%N/A-62.5%$169.40M$1.74M0.0090Positive NewsShort Interest ↓NVCTNuvectis Pharma3.4828 of 5 stars$6.38-2.7%$15.33+140.3%-5.2%$167MN/A-5.458Positive NewsMCRBSeres Therapeutics3.2128 of 5 stars$19.52+3.1%$73.67+277.4%-17.1%$165.81M$126.32M-4.24330LFVNLifevantage3.9996 of 5 stars$13.55+3.4%$30.50+125.1%+14.2%$164.90M$200.16M19.64260High Trading VolumeKYTXKyverna Therapeutics3.2118 of 5 stars$3.59-3.2%$16.60+362.4%-43.9%$160.44M$7.03M-0.9896Positive NewsMEIPMEI Pharma0.9724 of 5 stars$4.85-0.2%N/A+4.2%$159.59MN/A-1.02100Upcoming EarningsGap UpBDTXBlack Diamond Therapeutics3.4466 of 5 stars$2.80+1.8%$12.40+342.9%-44.4%$156.57MN/A12.1790Positive News Related Companies and Tools Related Companies ALT5 Sigma Alternatives biote Alternatives Citius Oncology Alternatives China SXT Pharmaceuticals Alternatives Nuvectis Pharma Alternatives Seres Therapeutics Alternatives Lifevantage Alternatives Kyverna Therapeutics Alternatives MEI Pharma Alternatives Black Diamond Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TELO) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TELO Stock Alerts